Jinxin Fertility Group Ltd. (HK:1951)
:1951
Top Page
Jinxin Fertility Group Ltd.
(1951)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$2.50
▲(0.81% Upside)
Action:ReiteratedDate:10/23/25
Jinxin Fertility Group Ltd. receives an overall stock score of 55, primarily driven by moderate financial performance with a stable balance sheet but concerning declines in net income and free cash flow. Bearish technical indicators further weigh on the score, reflecting a downward price trend. Valuation remains neutral with a negative P/E ratio offset by a modest dividend yield.
Positive Factors
Strong Financial Position
The company's robust financial health, characterized by consistent revenue growth and solid profitability, ensures long-term stability and operational efficiency, supporting sustainable business expansion.
Negative Factors
Revenue Decline
A decline in revenue growth poses a challenge to maintaining market position and profitability, potentially impacting long-term business sustainability and competitive advantage.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Financial Position
The company's robust financial health, characterized by consistent revenue growth and solid profitability, ensures long-term stability and operational efficiency, supporting sustainable business expansion.
Read all positive factors
Jinxin Fertility Group Ltd. (1951) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.86B
Dividend Yield2.38%
Average Volume (3M)20.30M
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth-8.56%
EPS Growth-403.12%
CountryHK
Employees3,198
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.03
Shares Outstanding2,757,706,000
10 Day Avg. Volume21,878,483
30 Day Avg. Volume20,304,545
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)0.70
Price to Sales (P/S)2.54
P/FCF Ratio14.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.31Price Target Upside33.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.09
Revenue Forecast (FY)HK$2.88B
Jinxin Fertility Group Ltd. Business Overview & Revenue Model
Company Description
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed ...
How the Company Makes Money
Jinxin Fertility Group generates revenue primarily through the provision of fertility treatments and services, with key revenue streams including fees for IVF procedures, consultations, and associated medical services. The company also earns incom...
Jinxin Fertility Group Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.66B | 2.81B | 2.79B | 2.36B | 1.84B | 1.43B |
| Gross Profit | 907.85M | 1.10B | 1.18B | 913.13M | 771.48M | 565.78M |
| EBITDA | 389.14M | 645.06M | 682.02M | 476.21M | 494.08M | 331.91M |
| Net Income | -946.50M | 283.10M | 344.72M | 121.12M | 339.90M | 251.62M |
Balance Sheet | ||||||
| Total Assets | 14.01B | 14.98B | 14.90B | 15.23B | 12.83B | 9.16B |
| Cash, Cash Equivalents and Short-Term Investments | 719.77M | 570.82M | 852.90M | 1.40B | 1.93B | 2.47B |
| Total Debt | 2.92B | 2.71B | 2.55B | 4.16B | 2.09B | 406.87M |
| Total Liabilities | 4.76B | 4.63B | 4.71B | 6.50B | 4.07B | 1.70B |
| Stockholders Equity | 9.19B | 10.27B | 10.09B | 8.64B | 8.55B | 7.28B |
Cash Flow | ||||||
| Free Cash Flow | 338.55M | 489.30M | 510.92M | -417.65M | 263.62M | 41.89M |
| Operating Cash Flow | 513.33M | 629.20M | 684.48M | 541.74M | 343.45M | 308.04M |
| Investing Cash Flow | -434.61M | -293.27M | -375.04M | -1.38B | -1.57B | 1.15B |
| Financing Cash Flow | -95.17M | -458.29M | -950.45M | 460.14M | 955.05M | -55.58M |
Jinxin Fertility Group Ltd. Technical Analysis
Positive
2.48
Price Trends
2.41
Positive
2.44
Positive
2.67
Negative
Market Momentum
<0.01
Negative
60.92
Neutral
96.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Positive. The current price of 2.48 is above the 20-day moving average (MA) of 2.33, above the 50-day MA of 2.41, and below the 200-day MA of 2.67, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.92 is Neutral, neither overbought nor oversold. The STOCH value of 96.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1951.
Jinxin Fertility Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$6.52B | 12.63 | 14.79% | 2.61% | 16.41% | 32.97% | |
66 Neutral | HK$1.56B | 5.35 | 18.05% | 4.37% | -3.56% | -17.45% | |
66 Neutral | HK$5.06B | 18.12 | 33.08% | 1.97% | 28.53% | 22.34% | |
62 Neutral | HK$7.54B | 43.03 | 0.62% | ― | -13.92% | -36.32% | |
55 Neutral | HK$6.86B | -6.17 | -10.66% | 2.38% | -8.56% | -403.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.59B | 20.66 | 5.64% | 1.20% | 2.05% | -285.88% |
* Healthcare Sector Average
HK:1951
Jinxin Fertility Group Ltd.
2.50
-0.74
-22.84%
HK:1526
Rici Healthcare Holdings Ltd.
0.98
-0.11
-10.09%
HK:2273
Gushengtang Holdings Limited
27.80
-1.28
-4.40%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
20.18
4.42
28.05%
HK:3309
C-MER Eye Care Holdings Limited
1.29
-0.09
-6.52%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
12.27
-1.25
-9.25%
Jinxin Fertility Group Ltd. Corporate Events
Jinxin Fertility Narrows IVF Volume Decline and Signals Recovery Momentum in 2025
Jan 5, 2026
Jinxin Fertility Group reported that its IVF treatment volumes continued to recover in the fourth quarter of 2025, with full-year 2025 IVF cycles down just 1.4% from 2024, a marked improvement from the 5.2% decline seen over the first three quarte...
Jinxin Fertility Group Approves 2025 Share Scheme at Extraordinary General Meeting
Dec 5, 2025
Jinxin Fertility Group Ltd. held an Extraordinary General Meeting on December 5, 2025, where all proposed resolutions were passed by poll. The key resolution approved was the adoption of the 2025 Share Scheme, which allows for the issuance and all...
Jinxin Fertility Group Announces Share Repurchase Plan
Dec 1, 2025
Jinxin Fertility Group Ltd. has announced a proposed on-market share repurchase, allowing the company to buy back up to 10% of its total issued shares. This move is intended to reflect the company’s confidence in its business prospects and t...
Jinxin Fertility Group Announces EGM and 2025 Share Scheme Details
Nov 19, 2025
Jinxin Fertility Group Limited has announced the book closure period for its Extraordinary General Meeting (EGM) scheduled for December 5, 2025. The meeting will address the proposed adoption of the 2025 Share Scheme, the conditional grant of opti...
Jinxin Fertility Group Announces 2025 Share Scheme to Boost Market Position
Nov 19, 2025
Jinxin Fertility Group Ltd. has announced an extraordinary general meeting to approve the adoption of a 2025 Share Scheme. This scheme includes granting share awards and options to eligible participants, with a significant allocation to Mr. Dong Y...
Jinxin Fertility Group Delays Circular Dispatch for 2025 Share Scheme
Nov 11, 2025
Jinxin Fertility Group Ltd. announced a further delay in the dispatch of a circular related to the 2025 Share Scheme and conditional grant of options and restricted shares to its directors and senior management. The delay is due to the need for ad...
Jinxin Fertility Announces Changes in Company Secretarial Roles
Oct 31, 2025
Jinxin Fertility Group Limited announced changes in its company secretarial positions, with Ms. Zhai Yangyang and Ms. Ng Sau Mei resigning from their roles as joint company secretaries and authorized representative, effective October 31, 2025. Ms....
Jinxin Fertility Group Reports Improved IVF Treatment Cycle Trends
Oct 23, 2025
Jinxin Fertility Group Limited announced a slowdown in the decrease of IVF treatment cycles for the nine months ending September 30, 2025, compared to the previous year. The company’s flagship hospital in Chengdu showed significant improveme...
Jinxin Fertility Group Delays Circular Dispatch for 2025 Share Scheme
Oct 20, 2025
Jinxin Fertility Group Ltd. announced a delay in the dispatch of a circular related to the proposed adoption of the 2025 Share Scheme and conditional grant of options and restricted shares to its directors and senior management. The delay is due t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.